Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Chronic Total Occlusion of Coronary Artery, Chronic Angina
Interventions: VasoStar guidewire system; Device
Lead sponsor: VasoStar, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia • Akron, Ohio

Conditions: Multiple Sclerosis
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fractional Flow Reserve, Myocardial, Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Centro Hospitalar Lisboa Ocidental; Government
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Biliary Tract Cancer, Cholangiocarcinoma
Interventions: Gemcitabine, Cisplatin, Durvalumab, Spatially Fractionated RT, Deep Hyperthermia; Drug · Radiation · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Depressive Disorder
Interventions: Transdermal Nicotine Patch, Transdermal Placebo Patch; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Vascular Lesions, Photoaging
Interventions: velos; Device
Lead sponsor: Syneron Medical; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: San Diego, California • Wayland, Massachusetts • Edina, Minnesota + 1 more

Conditions: Anorexia Nervosa
Interventions: Physiologic Estrogen/progesterone, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Cleveland, Ohio

Conditions: Nodular Basal Cell Carcinoma, Superficial Basal Cell Carcinoma
Interventions: 595/1064 multiplex laser; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Knee Osteoarthritis, CBD, Osteoarthritis
Interventions: Topical CBD Patch, Placebo Patch; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Normal Physiology, Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fanconi Anemia
Interventions: MRIs; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Coronary Artery Disease, Atherosclerosis
Interventions: NIRS-IVUS Imaging (TVC Imaging System); Device
Lead sponsor: Infraredx; Industry
Eligibility: Not listed
Enrollment: 1,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 31
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlantis, Florida + 25 more

Conditions: Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab; Drug · Other · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Tobacco Use Disorder
Interventions: Standard treatment plus brief alcohol intervention, Standard treatment (ST); Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Depression, Psychosis, Anhedonia
Interventions: Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions: therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate; Biological · Drug · Procedure + 1 more
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Neurofibromatosis 1
Interventions: Everolimus; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer Diagnosis
Interventions: Fine needle aspiration, Cancer Detection cartridge; Procedure · Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Lutherville-Timonium, Maryland

Conditions: Smoking Cessation, Smoking, Nicotine Dependence
Interventions: Nicotine patch, Cessation Counseling, Mobile Games; Drug · Behavioral · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Interventions: Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s); Drug · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Duarte, California • Orange, California + 17 more

Conditions: Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions: Fluorine F 18 DASA-23, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Guido A. Davidzon, MD, SM; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pituitary Adenoma, Pituitary Tumor
Interventions: Surgical intervention for CNFA, Radiotherapy for CNFA; Procedure · Radiation
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Performance of a New REsting Pressure Index During Invasive Angiography Compared To Adenosine Hyperemic FFR

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Depressed Mood Improvement Through Nicotine Dosing 3

VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation

Effects of Anorexia Nervosa on Bone Mass in Adolescents

Scan-Rescan Sub-Study of MS PATHS

Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser

The Use of Cannabinoid Patch for Knee Osteoarthritis

Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation

MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients

The Lipid-Rich Plaque Study

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Improving Smoking Cessation Outcomes in Heavy Drinkers - 1

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T

Automated Method for Breast Cancer Detection

A Quit Smoking Study Using Smartphones

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

Prospective Study of Clinically Nonfunctioning Pituitary Adenomas